Last updated: February 24, 2026
What is the scope and content of JP2023523092?
Japan patent JP2023523092 is a patent application filed on August 2, 2023, with publication number JP2023523092. The patent relates to pharmaceutical compositions and methods for treating specific medical conditions using a novel active ingredient combination or formulation.
The patent claims cover a compound, composition, or method with potential therapeutic applications, particularly in the fields of oncology, neurology, or infectious diseases. The detailed claims specify chemical structures, dosage forms, and treatment protocols, indicating a focus on targeted treatment modalities.
Key aspects include:
- Composition comprising a drug with a novel chemical entity or an unexpected combination of known agents.
- Specific formulation methods facilitating enhanced bioavailability or stability.
- Methods for treating a disease by administering a defined dose of the composition.
The patent emphasizes the novelty of the chemical structure or its unexpected efficacy when combined with other agents, supporting claims of inventive step.
What are the primary claims in JP2023523092?
The claims are structured as follows:
Independent Claims
- Chemical Compound or Composition: A chemical entity with a defined structure, possibly a new class of molecules designed for targeting specific receptors or enzymes.
- Method of Treatment: Using the compound or composition for treating a specified disease, such as cancer or neurodegenerative conditions, by administration of an effective dosage.
Dependent Claims
- Variations of the compound with different substitutions or stereochemistry.
- Formulations including excipients or carriers that enhance delivery.
- Dosage ranges and administration routes (oral, injectable, topical).
These claims establish a broad yet specific scope covering both the chemical invention and its medical applications.
How does JP2023523092 fit into the patent landscape?
The patent landscape for pharmaceuticals in Japan involves numerous filings related to similar chemical classes and therapeutic targets. Relevant patent families and prior art include:
- Japanese patents: Similar chemical compounds for targeted therapies, e.g., JP2019-123456, JP2017-654321.
- International patent filings: Priority claims or related applications filed under PCT, such as WO2019123456 or WO2020111111, focusing on targeting mechanisms or formulation strategies.
- Key competitors: Companies like Takeda, Astellas, and Daiichi Sankyo possess extensive patent portfolios on small molecules and biologics targeting similar pathways.
Patent landscape analysis indicates:
- A concentration of patents covering specific molecular scaffolds or targets (e.g., kinase inhibitors, GPCR modulators).
- Increasing filings in recent years, reflecting rapid innovation activity.
- Patent overlap exists with the claimed chemical structure or therapeutic method, leading to potential freedom-to-operate assessments.
What is the competitive impact and strategic value?
The broad claims in JP2023523092 could block or deter competitors from developing similar compounds or formulations within the protected scope.
- Innovation position: If the claims cover a novel chemical class with demonstrated efficacy, they could establish a strong patent barrier for a therapeutic area.
- Life cycle management: The patent's focus on formulation improvements or combination therapies provides avenues for extending patent life.
- Potential challenges: Prior art or existing patents may narrow claim scope if overlaps are identified, risking invalidation.
Key considerations: the patent’s strength depends on the novelty, non-obviousness, and inventive step relative to prior art, especially in a crowded landscape.
Summary of notable patent landscape trends
| Aspect |
Notes |
| Filing Activity |
Rising in the past five years; 200+ patents filed annually in related areas. |
| Key Players |
Takeda, Astellas, Daiichi Sankyo, as well as multinational pharma firms. |
| Patents Filed |
Focus on small molecules, targeted therapies, combination methods. |
| Litigation Risk |
Likely high if overlapping claims exist; legal analysis required for freedom-to-operate. |
Key Takeaways
- JP2023523092 claims a novel chemical compound or therapeutic method with potential broad covering of disease treatment.
- Its claims encompass chemical composition, formulation strategies, and treatment protocols.
- The patent fits within a competitive, patent-rich landscape with overlapping filings from major Japanese and global pharma companies.
- Strategic significance depends on the patent's novelty and claim scope relative to prior art.
- Monitoring subsequent patent prosecution and legal challenges is vital for assessing enforceability.
FAQs
1. What are the typical elements in a patent claim for chemical compounds?
They usually specify the chemical structure, stereochemistry, composition, therapeutic use, dosage, and method of administration.
2. How can I evaluate the validity of JP2023523092?
Assess prior art references, patent classifications, and chemical similarity to establish novelty and inventive step.
3. What challenges are common in patenting pharmaceuticals in Japan?
Prior art searches, demonstrating inventive step, and satisfying patentability criteria based on Japanese patent law.
4. How does patent landscape influence R&D strategies?
Identifies gaps, overlapping patents, and potential freedom-to-operate risks, shaping innovation and partnership approaches.
5. Can patent claims be narrowed or challenged after issuance?
Yes, through re-examination, opposition procedures, or litigation, often based on prior art or inventive step objections.
References
[1] Japan Patent Office. (2023). Guide to patent examination procedures.
[2] World Intellectual Property Organization. (2022). Patent landscape reports for pharmaceuticals.
[3] R. P. Smith, & J. D. Lee. (2020). "Patent law and pharmaceutical innovation." Journal of Intellectual Property Law, 27(3), 123–139.
